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Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue
sarcomas that can arise either sporadically or in association with
neurofibromatosis type 1 (NF1). These aggressive malignancies
confer poor survival, with no effective therapy available. We pres-
ent the generation and characterization of five distinct MPNST
orthoxenograft models for preclinical testing and personalized
medicine. Four of the models are patient-derived tumor xenografts
(PDTX), two independent MPNSTs from the same NF1 patient and
two from different sporadic patients. The fifth model is an
orthoxenograft derived from an NF1-related MPNST cell line. All
MPNST orthoxenografts were generated by tumor implantation, or
cell line injection, next to the sciatic nerve of nude mice, and were
perpetuated by 7–10 mouse-to-mouse passages. The models
reliably recapitulate the histopathological properties of their
parental primary tumors. They also mimic distal dissemination
properties in mice. Human stroma was rapidly lost after MPNST
engraftment and replaced by murine stroma, which facilitated
genomic tumor characterization. Compatible with an origin in a
catastrophic event and subsequent genome stabilization, MPNST
contained highly altered genomes that remained remarkably stable
in orthoxenograft establishment and along passages. Mutational
frequency and type of somatic point mutations were highly
variable among the different MPNSTs modeled, but very consistent
when comparing primary tumors with matched orthoxenografts
generated. Unsupervised cluster analysis and principal component
analysis (PCA) using an MPNST expression signature of ~1,000
genes grouped together all primary tumor–orthoxenograft pairs.
Our work points to differences in the engraftment process of
primary tumors compared with the engraftment of established cell
lines. Following standardization and extensive characterization
and validation, the orthoxenograft models were used for initial
preclinical drug testing. Sorafenib (a BRAF inhibitor), in combina-
tion with doxorubicin or rapamycin, was found to be the most
effective treatment for reducing MPNST growth. The development
of genomically well-characterized preclinical models for MPNST
allowed the evaluation of novel therapeutic strategies for person-
alized medicine.
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Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are rare malig-
nancies with a peripheral nerve sheath origin. MPNSTs account for
3–10% of all soft tissue sarcomas and are a highly aggressive histo-
logical subtype, with an incidence in the general population of 1 per
100,000 (Ducatman et al, 1986; Collin et al, 1987; Evans et al,
2002). Approximately half of MPNSTs develop in patients with
neurofibromatosis type 1 (NF1), while the other half develop
sporadically (Evans et al, 2002; Ferner & Gutmann, 2002; Carli et al,
2005). NF1 is a common autosomal dominant tumor predisposition
syndrome occurring in 1 in 3,500 individuals world-wide (Huson
et al, 1989; Evans et al, 2002). NF1 patients develop benign dermal
and plexiform neurofibromas and MPNSTs. Inactivation of the
remaining NF1 wild-type allele is essential for neurofibroma forma-
tion, although genetically engineered mouse models have shown
that a heterozygous NF1 (+/) cell environment is important for its
development (Zhu et al, 2002). In NF1, MPNSTs commonly arise
within a preexisting plexiform neurofibroma (Ducatman et al,
1986). The lifetime risk of MPNST development in NF1 patients is
around 8–13%, and these sarcomas are the leading cause of morta-
lity and morbidity in adults with NF1 (Rasmussen et al, 2001; Evans
et al, 2002). Due to the disease progression and metastatic potential,
both sporadic and NF1-related MPNSTs are considered tumors
of poor prognosis (Ferner & Gutmann, 2002; Porter et al, 2009).
The therapeutic approach for all MPNSTs comprises surgical
excision followed by radiation and/or chemotherapy (Ducatman
et al, 1986; Carli et al, 2005; Dilworth et al, 2006; Porter et al, 2009;
Moretti et al, 2011). The 5-year survival rate after MPNST diagnosis
in a NF1 patient is 20–50%, with a higher survival rate in sporadic
cases (Evans et al, 2002). Treatment failure is often associated with
bone and lung metastases (Ducatman et al, 1986; Wong et al, 1998;
Anghileri et al, 2006). Standard sarcoma chemotherapy regimens
are indicated for the treatment of MPNSTs.
Different strategies have been developed to generate in vivo
tumor models that may resemble human MPNST and could be used
to assess effective, standardized therapies. Subcutaneous and ortho-
topic xenograft MPNST models have been generated from both
sporadic (Mahller et al, 2007; Johansson et al, 2008; Lopez et al,
2011) and NF1 tumors, from established cancer cell lines in all cases
(Perrin et al, 2007; Banerjee et al, 2010; Lopez et al, 2011; Turk
et al, 2011). To date, only one model has been derived from a
primary MPNSTs, but this was subcutaneously engrafted (Bhola
et al, 2010). A genetically engineered mouse model carrying linked
germline mutations in Nf1 and Tp53 or Pten has also been devel-
oped and used in several drug trials (Cichowski et al, 1999; Vogel
et al, 1999; Keng et al, 2012).
Several therapeutic approaches have been evaluated in preclini-
cal models (Killion et al, 1998; Mahller et al, 2007; Ambrosini et al,
2008; Johansson et al, 2008; Demestre et al, 2010; Jessen et al,
2013; Ohishi et al, 2013), most of which target the RAS-MAPK
signaling pathway and the mTOR pathway (Basu et al, 1992; DeClue
et al, 1992; Guha et al, 1996; Downward, 2003; Watson et al,
2014), which is expected to be over-activated upon NF1 mutation
(Guha et al, 1996; Sherman et al, 2000). However, the results of
these assays are inconclusive or limited to certain models. Two
recent phase II clinical trials assessed the monotherapy activity of
sorafenib or rapamycin analogs (temsirolimus) in patients with
different types of sarcoma, including MPNSTs (Maki et al, 2009;
Okuno et al, 2011). In general, no objective responses were
observed in this subset of patients when using a single drug treat-
ment.
Here, we describe the establishment and comprehensive charac-
terization of a library of orthotopic patient-derived xenograft
MPNST models from sporadic and NF1 patients. Our results demon-
strate that perpetuated orthotopic patient-derived tumor xenografts
(PDTXs) closely resemble primary tumors and allow preclinical
evaluation of personalized therapeutic approaches.
Results
Development of orthoxenograft mouse models of MPNSTs
We generated five MPNST orthoxenograft mouse models: two from
sporadic tumors, two from independent tumors of the same NF1
patient, and one corresponding to the engraftment of the MPNST
cell line S462 (Fig 1 and Table 1). None of the primary tumors
received radiotherapy or chemotherapy prior to surgery. Human
tumors (2–3 mm3) were grafted onto the sciatic nerve of nude mice
following the procedure outlined in Materials and Methods.
Orthoxenograft mouse MPNST models closely resemble
primary tumors
Having established and standardized the orthoxenograft models, we
performed an exhaustive histological and molecular characterization
of MPNSTs and orthoxenografts, comparing each primary tumor to
its corresponding orthoxenograft at passages 1 and 4.
Histological validation
Hematoxylin–eosin staining showed similar histopathological
patterns between primary tumors and orthoxenografts at passages 1
and 4 (Fig 2A and Supplementary Fig S1A). In addition, analysis of
the soft-tissue tumor marker vimentin showed positivity in all
models, while three canonical non-nerve tumor markers (epithelial
membrane antigen, desmin, and smooth muscle actin) were all
negative (Table 2, Fig 2B and Supplementary Fig S1B). The endo-
thelial marker CD34 was shown to be positive in two of the NF1
tumor models (including the corresponding primary tumors) but
negative for the rest of cases. S100, a neural differentiation marker
that stains all benign Schwann cell tumors but only ~50% of
MPNSTs (Khalifa et al, 2000), revealed positivity in all sporadic
models but was negative for the NF1 tumors. As measured by Ki-67
staining, the rate of tumor cell proliferation was similar for all cases
(positivity 25–35%) with the exception of S462 cells, which showed
a higher proliferation rate (~80%); similar results were observed
using P53 staining (Table 2, Fig 2B and Supplementary Fig S1B).
To investigate distal dissemination properties, lung, brain, and
liver from sacrificed mice were histologically analyzed for the pres-
ence of micrometastases. Synchronic micrometastases were identi-
fied in lung from three of the models (MPNST-SP-001, MPNST-SP-
002, and the orthotopically engrafted S462 cell line) (Supplementary
Fig S2), but no liver or brain metastases were identified. Moreover,
to better characterize the metastatic phenotype, one of the synchro-
nous micrometastases of MPNST-SP-002 was immunochemically
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Figure 1. Development of orthoxenograft mouse models of MPNSTs.
Five orthotopic xenograft mice models were established from four different MPNSTs and one cell line. Two of the MPNSTs come from the same NF1 patient; the other two
were sporadic cases. Primary tumor (2–3 mm3) or tumor cell line (3 × 106 cells) were grafted or injected in the leg of athymic nudemice, close to the sciatic nerve. Tumors were
perpetuated along several passages and subsequently expanded. Several assays were performed on tumors in early passages (histopathological analysis, gene expression
profiling, genomic profiling, and drug efficacy studies). *NF1-MPNST-001 at passage 4 (P4) and all primary tumors and orthotopic tumors (OT) at passage 1 (P1) were analyzed
by exome sequencing and immunohistochemistry. All primary tumors and orthotopic tumors at passages 1 and 4were analyzed by expression array (except NF1-MPNST-001
PT, SP-MPNST-001 OT P4, and NF1-S462 OT P4). Copy number analysis (CNA) was performed in all samples.
Table 1. Clinical characteristics of patients and tumors used to generate the xenograft models.
Tumor ID Age Sex Ethnicity NF1 patient Germline NF1 MPNST Tumor grade Location
Somatic
NF1
MPNST-NF1-001 34 M EU (Spain) Yes c.350T>A Primary IV Thigh LOH
MPNST-NF1-002 37 M EU (Spain) Yes c.350T>A Primary III Arm LOH
MPNST-SP-001 88 M EU (Spain) No – Primary IV Laterocervical c.3520C>T
MPSNT-SP-002 74 F EU (Italy) No – Relapse IV Arm –
MPNST-NF1-S462 19 F EU? (Germany?) Yes c.6792C>A Cell line IV Thigh LOH
EU, European.
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Figure 2. Orthoxenograft mouse MPNST models closely resemble primary tumors.
A Orthotopic MPNST xenografts at passages 1 (OT P1) and 4 (OT P4) were histopathologically similar to their corresponding primary MPNST (PT) in hematoxylin–eosin
staining of paraffin-embedded tumor sections from patients MPNST-NF1-001 and MPNST-SP-002. Main panels show a general view of the tumors at low
magnification (40×); inset pictures were taken at higher magnification (400×).
B Orthotopic xenograft and primary MPNSTs exhibited similar immunohistochemical features. A representative immunostained section of vimentin, CD34, S100, and
Ki-67 is shown for primary tumors (PT) and orthotopic tumors (OT) from patients MPNST-NF1-001 and MPNST-SP-002. Positive antibody signals are shown in brown,
and the hematoxylin counterstain in blue. Main panels show pictures at high magnification (400×); inset pictures show mitotic cells present in these tumors.
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characterized using four antibodies: vimentin, CD34, S100, and
Ki-67, which were a perfect match with the corresponding ortho-
xenograft MPNSTs (Supplementary Fig S2).
A subgroup of orthotopically implanted mice (the two sporadic
models and MPNST-NF1-001) was kept alive for 4–6 months after
tumor removal to investigate the dissemination capabilities over a
longer time frame. Metachronic micrometastases were only identi-
fied in the lung from one sporadic MPNST tumor (Supplementary
Fig S2).
Human stroma is lost after engraftment and replaced by
murine cells
Due to the importance of tumor microenvironment in tumor behav-
ior and response to therapy, it was important to understand the
nature of the stroma in the MPNST orthoxenografts generated.
Thus, we next analyzed the fate of human non-tumor stromal cells
after primary MPNST engraftment. Staining with anti-human CD34
clearly labeled vessels in primary tumors but not in orthoxenografts.
By contrast, an antibody for the identification of mouse CD34 only
labeled vessels in the orthoxenograft samples and not in the primary
tumor (Fig 3A and Supplementary Fig S3). In addition, when
attempting to derive cell lines from first-passage MPNST orthoxeno-
grafts, a rapid overgrowth of murine fibroblasts was observed
immediately after plating (data not shown), indicating the presence
not only of murine vessels but also mouse stromal fibroblasts.
As both copies of the NF1 gene are inactivated in NF1-associated
MPNST, non-malignant stromal cells can be identified as those
carrying only the constitutional mutation but not bearing a second
NF1 hit. We analyzed the NF1 patient-derived MPNSTs (NF1-001
and NF1-002) for the presence of mutation c.350T>A (germline hit)
and for the second NF1 hit (LOH in both tumors). The sequence of
the NF1 region containing the constitutive mutation revealed WT
NF1 alleles in primary tumor samples, indicating the presence of
normal human cells (Fig 3B). By contrast, WT NF1 alleles were
cleared out in the corresponding derived orthoxenografts, indicating
probable loss of the human stromal cells (Fig 3B). We then
analyzed SNP array data from both tumors and corresponding xeno-
grafts, using ASCAT to estimate the percentage of normal cells pres-
ent in both sample types. These results corroborated the loss of
human stroma cells in orthoxenografts from the first engraftment
(passage 1) (Fig 3C). Further analysis of SNP array data from
sporadic MPNSTs showed a similar pattern of stromal loss.
Molecular validation
In addition to a thorough histological validation of the developed
MPNST orthoxenograft models, we performed extensive molecular
characterization at the genomic and transcriptomic levels of primary
tumors and orthoxenografts by SNP array, exome sequencing, and
expression array analyses.
Genomic copy number and allelic imbalance analysis
MPNSTs are characteristically composed of tumor cells containing
highly altered genomes at a structural level (Forus et al, 1995;
Mertens et al, 1995, 2000; Mechtersheimer et al, 1999; Mantripragada
et al, 2008, 2009; Beert et al, 2011). Accordingly, we characterized
the somatic copy number alterations (SCNAs) and allelic imbalances
(AIs) present in primary tumors and paired orthoxenografts and
performed an exhaustive comparison.
We first analyzed tumor MPNST-NF1-001 by comparing the
primary tumor with the orthoxenografts at passages 1 and 4 from
two lineages representing two independent engraftments (Fig 4).
SNP array data from these five samples were analyzed using
ASCAT. Comparison of the primary tumor with the four orthoxeno-
grafts allowed us to detect genomic alterations along xenograft
passages, assessing the genomic stability of the engrafted tumor,
and differences between two primary engrafted independent
lineages, assessing the reproducibility of the orthoxenograft model.
As expected, the genome of the primary MPNSTs and orthoxeno-
grafts was highly altered, mainly presenting gains of whole chromo-
somes or large chromosomal regions and a few losses of genetic
material. In addition, B-allelle frequency (BAF) plots showed several
patterns consistent with complex rearrangements and large regions
exhibiting LOH (Fig 4). A global view of the genomic alteration
profiles showed a high degree of similarity between the primary
tumor and the 4 derived orthoxenografts. In this case, due to the
high proportion of non-altered stroma cells in the primary tumor
sample, the raw data were strongly biased toward a diploid hetero-
zygous genome; hence, the variant calling algorithm used reported
fewer alterations in the primary tumor than in orthoxenografts.
However, visual inspection of the raw data revealed that almost all
Table 2. Immunohistochemical characterization of human tumors and their first derived xenograft mouse models.
Antibody
MPNST-NF1-001 MPNST-NF1-002 MPNST-SP-001 MPNST-SP-002 MPSNT-NF1-S462
PT OT PT OT PT OT PT OT CL OT
Vimentin + + + + + + + + + +
Desmin          
Actin         (+ focal)   (+ focal)
EMA          
CD34 + +   (+ focal)     + +
S100     + + + +/  
P53 15% 15% <5% 20% <5% <5% 20% <5% 80% 80%
Ki-67 25% 25% 25–30% 35% 35–40% 20% 25–30% 25–30% 90–95% 80%
PT, primary tumor; OT, orthotopic xenograft tumor; CL, cell line.
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alterations identified in orthoxenografts were present in primary
tumors (see Fig 4). Furthermore, these differences were not present
in the rest of the primary tumor versus orthoxenograft comparisons,
since these tumors contained a lower proportion of 2n cells (Supple-
mentary Fig S4A and B). The comparison of BAF plots between
primary tumor and orthoxenograft passages 1 and 4 was consistent
with the progressive depletion of human 2n cells along passages. In
addition, the analysis of multiple orthoxenograft passages revealed
that this highly altered genome remained stable along successive
xenograft passages (Supplementary Fig S4A and B). The differences
in BAF between orthoxenografts at passage 1 and passage 4 that
were not compatible with progressive stromal removal were inter-
preted as structural genomic changes caused by the successive
engraftments (highlighted in Supplementary Fig S4A and B). Over-
all, comparative analysis of the primary tumor and the serial
passages of the orthoxenograft models indicated that, on average,
< 7% of the orthoxenograft genome presented structural changes
(copy number alterations and allelic imbalances) relative to the
primary tumor.
To overcome any bias produced by different proportions of 2n
stromal cells in the primary tumors, we compared passage 1 ortho-
topic xenografts, in which the human stroma was strongly reduced
(Fig 3 and Supplementary Fig S3). Both the sporadic and NF1-
related tumors presented a highly altered genome with several copy
number alterations, ranging from 215 in MPNST-NF1-001 to 401 in
MPNST-NF1-002, affecting the majority of the genome (from 71% in
MPNST-NF1-001 to 84.9% in MPNST-SP-002). LOH was of 38.3 and
61.2% in NF1-related tumors (MPNST-NF1-001 and MPNST-NF1-
002) and of 3.8 and 24% in sporadic cases (MPNST-SP-001 and
MPNST-SP-002, respectively) (Supplementary Fig S4A and B).
Exome sequencing
Exome sequencing was used to characterize and compare genetic
variation caused by point mutations in genomic coding regions pres-
ent in constitutional DNA, primary tumors, the S462 cell line, and
matched orthoxenograft MPNST models. The minimum coverage
needed for reliable variant calling was set at 20×, and regions above
A B
C
Figure 3. Human stroma is lost after engraftment and replaced by murine cells.
A Stromal elements of the primary tumors were labeled with anti-human CD34 but not anti-mouse CD34; patient-derived xenografts are labeled with anti-mouse CD34
only and no anti-human marker. Representative sections (at 40× and 400× magnification) of the primary tumors (PT) and the orthoxenograft tumors at passages 1
(OT P1) and 4 (OT P4) were labeled with anti-human CD34 (H) and anti-mouse CD34 (M).
B Sanger sequencing of the germline NF1 mutation c.350T>A present in the patient that developed two different tumors (MPNST-NF1-001 and MPNST-NF1-002).
Sequencing results from normal tissue, primary tumor (PT), and orthotopic xenograft tumors (OT) are shown. The sequence of the NF1 region revealed WT NF1 alleles
in primary tumor samples, and not in the corresponding derived orthoxenografts, indicating probable loss of the human stromal cells.
C SNP array of primary tumor (PT) and orthotopic xenograft passages 1 (OT P1) and 4 (OT P4) for MPNST-NF1-001 and MPNST-NF1-002 tumors. Results correspond to
chromosome 17. Images show the B-allele frequency (BAF) for the different samples as scatter plots and the copy number callings below them represented by thick
horizontal lines: 2n regions are shown in gray, gained regions in orange, lost regions in green, and LOH regions are represented in blue. The vertical red line indicates
the location of the NF1 locus. In addition, the percentage of tumor versus stromal cells for each sample is represented in a pie chart (blue, stromal cells; red, tumor
cells).
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Figure 4. Orthotopic xenograft MPNSTs maintain the genomic structure found in primary tumors.
Genome-wide SNP array profiling from two different orthoxenograft tumors derived from the same primary tumor (MPNST-NF1-001) are shown as Circos plots. The
outermost layer contains the set of canonical human chromosomes. The following layers, from outside to inside, illustrate the following: the BAF of the primary tumor (A),
and the derived xenografts at passages 1 (B and C) and 4 (D and E). Copy number variations are represented by a colored line under each BAF (gray: 2n, red: > 2n (chromosomal
gain); green: < 2n (chromosomal loss)). LOH events are shown in blue. Finally, differences between primary and xenograft tumors not compatible with the loss of signal from
stroma cells are highlighted in orange.
EMBO Molecular Medicine Vol 7 | No 5 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Establishment of PDTX-MPNST mouse models Joan Castellsagué et al
614
Published online: March 25, 2015 
this threshold (well covered regions, WCR) were identified in all
samples related to the same primary tumor (primary related
samples, PRS). The length of the different PRS-WCR ranged from
16.9 Mb for MPNST-NF1-001-PRS to 44 Mb for MPNST-SP-001-PRS.
Only variants present in PRS-WCR were taken into account when
comparing samples within each PRS (Supplementary Table S1).
The number of somatic mutations identified in PRS-WCR varied
between PRSs and ranged from 22 in MPNST-NF1-002-PRS to 755 in
MPNST-SP-001-PRS. When comparing tumors and xenograft pairs at
passage 1, just after engraftment, a mean of ~9 (0–33) mutations was
identified in orthoxenografts that were not present in primary tumors
(Fig 5) (Supplementary Table S1). New mutations were scattered
over the genome and showed no apparent clustering except for three
intronic mutations in the TTN gene. Of a total of 1,409 somatic muta-
tions identified in the four primary tumors, only 6 (3 in MPNST-NF1-
002-OT1 and 3 in MPNST-NF1-001-OT4) were not detected in the
orthotopic xenograft models and therefore classified as lost in the
engraftment process (data not shown). Altogether, the low number
of new and lost point mutations detected in the engrafted tumors
with respect to their primary counterparts reinforces our observation
that the orthotopic xenograft MPNSTs generated for this study
recapitulate the characteristics of the primary tumors.
A striking difference in the number and type of somatic point
mutations was observed when comparing NF1-derived and sporadic
models. In order to remove any bias due to different coverage
depths, we identified the regions with a read coverage of 20× or
higher in all exome-sequenced samples and termed them All-Well
Covered Regions (All-WCR). The All-WCR contained a total of
16.76 Mb of exons and exon–intron boundaries. Only point muta-
tions in these regions were taken into account when comparing
sporadic and NF1-related tumors. Thirty somatic point mutations
were identified in MPNST-NF1-001 and 15 in MPNST-NF1-002.
However, the number of somatic point mutations was an order of
magnitude higher in sporadic MPNST: 308 in MPNST-SP-001 and
257 in MPNST-SP-002 (Supplementary Fig S5A). Consequently, the
mutational frequency in common regions was 1.79 and 0.89 muta-
tions per megabase for MPNST-NF1-001 and MPNST-NF1-002,
respectively, and 18.38 and 15.33 mutations per megabase for
MPNST-SP-001 and MPNST-SP-002, respectively.
Among the total number of somatic point mutations identified in
the PRS-WCR, the frequency of different types of base changes also
differed between sporadic and NF1-related tumors. While mutations
in NF1-related tumors did not accumulate any particular base
change, sporadic tumors were highly enriched in C>T mutations
(Supplementary Fig S5B), which represented 79.07 and 85.98% of
the somatic mutations in MPNST-SP-001 and MPNST-SP-002,
respectively. Analysis of the mutation context of C>T mutations in
the sporadic primary tumors MPNST-SP-001 and MPNST-SP-002
Figure 5. Exome-sequencing analysis.
Number of somatic point mutations identified in primary tumors and new mutations acquired in the orthoxenograft models in PRS-WCR. Somatic mutations found in
primary tumors in sporadic cases were maintained in the orthoxenograft-derived tumors, whereas few acquired mutations were observed in all NF1-derived models. PT,
primary tumor; OT, orthotopic xenograft tumor; passage 1 (P1); passage 4 (P4).
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(Supplementary Fig S5C) revealed an enrichment in TpC (56.78 and
57.48%, respectively) and a lower but significant enrichment in CpC
(30.32 and 34.17%, respectively).
Expression analysis
Gene expression levels are influenced by different biological processes
at the genomic and epigenomic levels. Thus, gene expression analysis
can provide an integrative and more functional overview of the state
of a tumor. Accordingly, expression array analysis was performed to
validate the orthoxenograft models at the gene expression level. We
observed a high global correlation between the normalized expression
values for primary tumors and orthoxenografts at passage 1 (R2 ~0.9)
and an even higher correlation between the values at passage 1 and
passage 4 (R2 ~0.98), which is consistent with the removal of stromal
cells (Fig 6). We then analyzed a subset of ~1,000 genes representing
a molecular signature associated with NF1-peripheral nerve sheath
tumors, differentiating benign tumors from malignant tumors and
derived cell lines (Miller et al, 2009). Using this signature, the analy-
sis reported an even closer correlation between orthoxenografts and
the corresponding primary tumors (R2 ~0.95); by contrast, using the
same signature, lower correlation values were reported between
distinct primary tumors (R2 ~0.78) and between primary tumors and
non-corresponding xenografts (R2 ~0.8) (Fig 6A). Unsupervised clus-
tering analysis organized all of the samples analyzed, with each
primary tumor grouped with the corresponding derived orthoxeno-
grafts at different passages (Fig 6B). This analysis also classified the
samples in two groups: NF1-related (including the S462 cell line and
derived xenograft) and sporadic cases (Fig 6B). This classification
was obtained using both the molecular signature for NF1-related
MPNST and the whole expression profile.
Finally, PCA was performed using the gene expression levels of
the molecular signature; primary tumors were perfectly grouped
with their corresponding derived orthoxenografts (Fig 6C). At the
same time, the first component separated NF1-associated MPNST
and models from sporadic cases, while the second component sepa-
rated primary tumors and orthoxenografts from the S462 cell line
and its derived orthoxenograft (Fig 6C).
Using preclinical orthoxenograft MPNST models to test drug
treatment regimens
As the orthoxenografts tumor models were found to closely recapit-
ulate the human disease at the histopathological, genomic, and
transcriptomic levels, they were used to test clinically relevant thera-
peutic approaches. The four PDTX plus the orthoxenograft derived
from the NF1-cell line S462 were treated in monotherapy with:
(i) doxorubicin, the standard clinical chemotherapeutic agent, (ii)
oral and (iii) intraperitoneal rapamycin, an allosteric mTOR inhibitor,
and (iv) sorafenib, a BRAF inhibitor, or with combined drug
regimens (v) doxorubicin + rapamycin, (vi) doxorubicin + sorafenib,
and (vii) rapamycin + sorafenib. Both short- and long-term responses
were evaluated (Fig 7A and B, respectively).
Doxorubicin as a single agent achieved a significant response
relative to the placebo-treated animals in only one model (SP-002),
whereas non-significant differences were observed in the other
models. Intraperitoneal administration of rapamycin decreased
tumor size in all tested models (we were unable to perform this drug
treatment for the MPNST-NF1-S462 model due to a limited number
of mice), whereas orally administrated rapamycin showed no effect
on tumor growth. Sorafenib as a single therapy achieved a signifi-
cantly better response than rapamycin and doxorubicin in all of the
treated tumors. Notably, the combined sorafenib + doxorubicin and
sorafenib + rapamycin treatments proved to be more active than
either drug administered separately, suggesting a synergistic
effect. Furthermore, the combined sorafenib + doxorubicin treatment
A B C
Figure 6. Gene expression profiles between primary and orthotopic xenograft MPNSTs are similar.
A Heat map showing the correlations between expression levels of genes in the molecular signature of MPNSTs.
B Hierarchical clustering of tumors and xenografts groups all primary tumors with their derived orthoxenografts. Moreover, sporadic tumors and NF1-related tumors
form two different clusters.
C PCA of genes in the molecular signature of MPNSTs. All primary-xenograft pairs cluster together. The first component distinguishes between sporadic and NF1-related
tumors; the second component differentiates primary tumors (and derived orthoxenografts) from the cell line (and the derived orthoxenograft).
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AB
Figure 7. Preclinical orthoxenograft MPNST models to test drug treatment regimens.
A Tumor growth effects of treatment with doxorubicin, sorafenib, rapamycin and combinations thereof in the five MPNST xenograft models. Results are plotted as an
average of the log2 ratio of tumor volume at different days relative to the initial value. Statistically significant differences are shown as *P < 0.05 and **P < 0.001
versus control group by the Bonferroni test.
B For long-term studies, a subgroup of treated mice (n = 3–5 mice/group) was kept alive for a maximum period of 4 months and sacrificed over time when relapsed
tumor masses grew as large solid masses (usually 1,500–2,000 mm3). The graph illustrates differences in the time delay (in days) of relapsed tumor masses for the
different treatments.
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achieved the most effective short-term response in all MPNSTs.
Nevertheless, the sorafenib + rapamycin combination showed far
more significant tumor reduction in NF1-related cases than in
sporadic cases (Fig 7A).
To investigate the long-term response, a subgroup of treated
mice (n = 3–5 mice/group) were kept alive post-chemotherapy.
Figure 7B summarizes the time that tumor relapse took place for the
four PDTX-MPNST orthoxenografts for each single and combined
treatment. Long-term response studies confirm that combined
sorafenib + doxorubicin treatment was the most effective treatment
for the four models, suggesting a long-term synergistic antitumor
response for combined therapy. Thus, while for sorafenib monother-
apy treatments, tumor relapse took place in a period of 45–62 days,
depending on the tumor (NF1-001, 45 days; NF1-002, 51 days;
SP1-001, 48 days, and SP2-002, 35 days), for the combined
sorafenib + doxorubicin treatment, tumor relapse ranged from 88 to
112 days (NF1-001, 91 days; NF1-002, 112 days; SP1-001, 96 days,
and SP2-002, 88 days). Long-term response confirmed also the
effectiveness of combined sorafenib + rapamycin treatment for the
four PDTX, reinforcing their therapeutic effect, particularly in NF1-
derived models.
At the time of sacrifice, histopathological changes were assessed
in post-chemotherapy residual tumor masses for the different treat-
ments. Analysis was performed in the tumor as well as in the
surrounding stromal tissue for all treatments. To evaluate tumor
response, the levels of necrosis and the number of mitosis were
assessed (Table 3, Supplementary Fig S6). Viable cells were identi-
fied in the residual masses of all treatments, although increased
levels of necrosis were also seen for several treatments. The highest
levels of necrosis were observed in sorafenib + doxorubicin and
sorafenib + rapamycin treatments. Similarly, anti-proliferative effect
was confirmed for all the combined treatments: a significant
decrease was observed in the number of mitoses for the combined
sorafenib + doxorubicin and sorafenib + rapamycin treatments rela-
tive to single drug treatments (Table 3). Additionally, unlike PDTX
orthoxenografts, the cell line-derived tumor showed highly mitotic
index (Table 3). Together, our results showed the efficacy of
combined regimens using standard chemotherapy (doxorubicin)
with target therapy agents (mainly sorafenib, but also rapamycin) in
the treatment of the MPNST models described here.
Overexpression of ABCB5 and ASNS has been linked to resistance
to doxorubicin in different tumor types (Frank et al, 2005; Cheung
et al, 2011). Exome-sequencing analysis revealed three putative
mutations in the ABCB5 gene (one non-sense and two missense
variants) and one in the ASNS gene (a splice site variant) (Supple-
mentary Table S2). The two variants with the clearest loss-of-
function effect (the non-sense mutation in ABCB5 and the splice site
mutation in ASNS) were found in the same sporadic tumor
(MPNST-SP-002). This tumor exhibited the best response to doxoru-
bicin treatment, being potentially interesting for future pharmaco-
genetic studies.
Cell line versus primary tumor orthoxenograft models
In addition to the orthoxenograft models generated from primary
MPNSTs, we also developed an orthoxenograft model from an estab-
lished MPNST cell line (S462), following similar experimental proce-
dures used for the other models. Histological characterization of the
generated orthoxenograft showed that it retained the immuno-
cytochemical marker characteristics of the original cell line, as well
as reproducing the histological patterns of the NF1-associated
orthoxenografts (Table 2 and Supplementary Fig S1). At the molecu-
lar level, the number of point mutations and the expression
pattern indicated a high degree of similarity between the cell line
and the derived orthoxenografts (Figs 5 and 6). However, at the
structural genomic levels, the number of differences between the
S462 cell line and the orthoxenografts at passages 1 and 4 was
greater than observed in the MPNST-derived models (Fig 8 and
Supplementary Fig S4). These differences were classified in two
groups. The first group contained genomic changes identical to
those identified in models generated from primary tumors, that is,
differences between orthoxenograft passages 1 and 4, consistent
with structural genomic changes due to the successive engraftments
(highlighted in yellow in Fig 8). The percentage of genome affected
Table 3. Characterization of histopathological response in post-chemotherapy tumor masses of MPNST tumorsa.
MPNST-NF1-001 MPNST-NF1-002 MPNST-SP-001 MPNST-SP-002 MPNST-NF1-S462
Percentage
of necrosis
No. of
mitosis
Percentage
of necrosis
No. of
mitosis
Percentage
of necrosis
No. of
mitosis
Percentage
of necrosis
No. of
mitosis
Percentage
of necrosis
No. of
mitosis
Vehicle 0 8 0 12 18 26 7 6 10 99
Doxorubicin 5 5 0 3 20 19 0 2 10 27
Sorafenib 3 4 0 6 75 3 70 2 17 11
Rapamycinb 20 4 0 6 10 10 5 2 10 44
Doxorubicin +
Sorafenib
35 3 25 2 85 5 74 0.6 24 7
Doxorubicin +
Rapamycinb
30 9 0 7 30 14 10 2 12 12
Sorafenib +
Rapamycinb
35 2 30 0.8 70 3 80 0.6 40 10
aFor short-term drug response studies, the percentage of necrosis and the number of mitosis were evaluated by H&E staining of representative sections of the
residual tumor masses of 3–5 mice per group, as an indicator of chemotherapeutic response. Four non-overlapping representative fields were counted per tumor.
bOral administration of rapamycin.
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by these changes was low and similar to that observed in the other
models. The second group of differences corresponded to progres-
sive changes along passages that were consistent with a selection
process. We had previously observed a high diversity in the chromo-
somal content of S462 cells in culture by cytogenetic karyotyping
(data not shown), and these progressive changes from primary
tumor to passage 1 and passage 4 pointed to a clonal selection
process, reducing the heterogeneity of the original cell culture (high-
lighted in magenta in Fig 8).
Discussion
MPNSTs are aggressive malignancies associated with poor
survival and for which no effective therapy is available. We
considered that establishing preclinical models was a useful step
in developing an experimental framework for more accurate,
personalized testing of new therapeutic approaches. Our molecu-
lar understanding of cancer has been significantly expanded in
recent years thanks to the development of large-scale cancer
Figure 8. SNP array analysis of cell line S462 and its orthotopic xenograft tumors.
Orthotopic xenograft MPNSTs derived from cell line S462 showed a number of differences in genomic alterations when compared to the S462 cell line itself. The outermost
layer shows the full set of canonical human chromosomes. The next layers, from outside to inside, show the BAF of the S462 cell line (A), and its derived xenograft at passages 1
(B) and 4 (C). Copy number variations are represented by a colored line under each BAF (gray: 2n, red: > 2n (chromosomal gain); green: < 2n (chromosomal loss). LOH events
are shown in blue. Pink highlights mark the differences between cell line and xenografts compatible with a selection process, while orange highlights mark the regions
consistent with structural genomic changes due to engraftment process and passaging.
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genome initiatives such as TCGA or ICGC (International Cancer
Genome Consortium et al, 2010) aimed at identifying the genomic
alterations that drive the oncogenic process. However, the devel-
opment of novel therapeutic strategies is largely contingent on the
availability of preclinical models capable of recapitulating the
disease. Orthotopic PDTXs have proved to be excellent models for
this purpose because they preserve the key influence of the tumor
microenvironment, in contrast to in vitro cellular models or
subcutaneous xenografts (Richmond & Su, 2008; Kopetz et al,
2012; Tentler et al, 2012).
Histological analysis revealed a striking degree of concordance
in the histopathological and immunohistochemical patterns of the
primary tumor–xenograft pairs. Human stroma was rapidly lost after
MPNST engraftment and replaced by murine stroma, in agreement
with other reports (Xu et al, 1999; Sanz et al, 2009; DeRose et al,
2011; Hylander et al, 2013), greatly facilitating the genomic struc-
tural characterization of tumors, which is particularly crucial in the
case of primary tumors with large proportions of normal cells. Molec-
ular analysis at the genomic and transcriptomic levels also revealed a
high degree of similarity between primary MPNSTs and their corre-
sponding orthoxenografts. Genomic characterization confirmed
that MPNSTs bear highly altered genomes (Mechtersheimer
et al, 1999; Kresse et al, 2008; Mantripragada et al, 2009): an
average of 75.7% of the genome was found to exhibit copy number
alterations, with a high proportion of gains of whole chromosomes
or large chromosomal regions and complex chromosomal rearrange-
ments compatible with an origin in a catastrophic event (Stephens
et al, 2011; Baca et al, 2013; Zhang et al, 2013). This view was
supported by the fact that the complex genome structures remained
remarkably stable throughout the establishment of the orthoxeno-
grafts and along xenograft passages and did not reflect permanent
genomic instability. In fact, on average, < 6.8% of the genome
structure showed copy number alterations or allelic imbalance
changes in primary tumor–xenograft pairs. Exome analysis also
revealed little difference in coding region point mutations between
primary tumors and paired orthoxenografts, with a mean of 10
mutations in xenografts that were not present in the primary tumor.
We took an additional step in validating the orthoxenograft models
by analyzing biological status at the level of gene expression. Tran-
scriptomic analysis of ~1,000 genes representing a molecular signa-
ture associated with MPNSTs and cell lines relative to normal
Schwann cells and benign neurofibromas (Miller et al, 2006, 2009)
showed a high correlation between primary tumors and paired
orthoxenografts, even after several xenograft passages. All primary
tumor–orthoxenograft pairs clustered together in an unsupervised
cluster analysis and in a PCA, demonstrating the validity of the
models.
The generation of an orthoxenograft using the NF1-related
S462 MPNST cell line revealed differences in the engraftment
process between the direct grafting of primary tumors at the
sciatic nerve and the injection of cultured cell lines in the same
site. Although the orthoxenograft generated from the S462 cell line
reproduced the histological patterns of the NF1-associated ortho-
xenografts, genomic analysis showed progressive changes along
passages consistent with a cellular and genetic selection process
of the high heterogeneity present in in vitro cell cultures; a
process that was not observed in the engraftment of primary
tumors.
It is generally assumed that sporadic and hereditary cancer
sharing common inactivated pathways may be biologically similar,
although discussion is ongoing. The limited number of models
presented here is too low to draw any conclusion comparing these
two groups, since the effect of other intrinsic differences, such as
the mutation in the NF1 gene, the different age of the patients at
diagnosis, or the loss of linked genes on chromosome 17 during
LOH events, cannot be ruled out. Both MPNST types carried highly
altered and rearranged genomes, but while NF1-associated
MPNSTs seemed to have a higher degree of LOH than sporadic
MPNSTs, the latter contained a number of point mutations an
order of magnitude higher. Comparing the mutation frequencies
with those obtained across all cancer types (Lawrence et al, 2013;
Watson et al, 2013), the two NF1-associated MPNSTs developed in
the same patient (0.89–1.79 mutations per Mb) fall in the low
range of somatic mutation frequency, whereas the two indepen-
dent sporadic MPNSTs (15.33–18.38) are in the highest frequency
ranges. The high variation in mutation frequency within MPNSTs
is also common in many other cancer types (Baca et al, 2013) and
probably reflects current limitations in the classification of biologi-
cal tumor properties. When analyzing the mutation spectra to iden-
tify signatures of carcinogenesis mechanisms, we identified a
strong bias in sporadic MPNSTs toward a high frequency of C>T
base substitutions, which is consistent with the action of APOBEC3
(Stenglein et al, 2010; Nik-Zainal et al, 2012; Taylor et al, 2013).
The limited sequence data did not allow us to properly evaluate
mutation clusters, so we do not know whether kataegis are present
in the sporadic MPNST samples. Immunohistochemical character-
ization and gene expression analysis also revealed differences
between the two patient-derived NF1 tumors and the NF1-
associated MPNST cell line and the two independent sporadic
MPNSTs. Particularly significant results were obtained from the
unsupervised cluster analysis and the PCA using a molecular
signature of ~1,000 genes associated with MPNSTs, which clearly
separated the two MPNST types.
Finally, validated orthoxenograft MPNST models were used to
test the effect of different drugs or drug combinations. The treatment
experiments performed here demonstrated that the BRAF inhibitor
sorafenib reduced MPNST growth. Sorafenib is clinically approved
for the treatment of several cancer types such as kidney and liver
cancer (Escudier et al, 2007; Llovet et al, 2008). At the preclinical
level, good results have been reported in patients with advanced
angiosarcomas or in mouse models of pancreatic islet cell tumors
(Fendrich et al, 2012; Ray-Coquard et al, 2012). Sorafenib has been
tested in MPNST cell lines in vitro, showing a significant inhibition
of tumor growth, and data are available for in vivo models (Ambro-
sini et al, 2008). Altogether, these results strongly support the clini-
cal evaluation of sorafenib in this subset of patients. A recent phase
II clinical trial assessed the monotherapy activity of sorafenib in
patients with different types of sarcomas, including 12 patients with
MPNSTs. No objective responses were observed in nine of these
patients, although two experienced a certain grade of regression of
metastatic disease. Three patients showed stable disease, suggesting
the drug had only a small effect (Maki et al, 2009). Although the
results of the clinical trial do not appear very promising, sorafenib
should be considered in combination with other agents, particularly
taking into account the preclinical model results presented in this
study. The antitumor activity of rapamycin and its analogs has been
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demonstrated in several in vitro studies with MPNST cell lines
(Johansson et al, 2008; Zou et al, 2009; Endo et al, 2013) and in
some clinical trials (Chan, 2004). Our results show that intraperi-
toneal rapamycin practically stopped tumor growth in almost all
orthoxenografts. These results are consistent with other studies
using patient-derived subcutaneous tumor xenografts (Bhola et al,
2010). However, oral rapamycin had no effect on tumor progression,
in contrast to previous trials using subcutaneous xenografts derived
from cell lines (Johansson et al, 2008). These results may illustrate
the importance of the MPNST implantation site (subcutaneous or
orthotopic) or reflect poor drug delivery to tumors by oral adminis-
tration. In a recent clinical trial of temsirolimus (Okuno et al, 2011),
only 5% of sarcoma patients responded to treatment, and the only
patient with a MPNSTs did not respond. Although these are the first
in-human results of this treatment for sarcomas, the numbers are too
small to rule out the role of mTOR inhibitors as therapeutic agents,
in particular for MPNSTs. As our results indicate, a combination of
rapamycin and drugs targeting other pathways may be beneficial for
MPNST patients. Doxorubicin seemed to show a mild synergistic
effect in combination with rapamycin and with sorafenib, although it
has already been administered alone as a conventional chemother-
apy regime in patients with MPNSTs with poor outcomes (Ferner &
Gutmann, 2002; Casali et al, 2008). Interestingly, the MPNSTs that
showed the best response to doxorubicin treatment contained loss-
of-function mutations in both ABCB5 and ASNS (MPNST-SP-002).
The identification of mutations in these genes, which are involved in
resistance to drug treatment, opens the possibility of combining
inhibitors of these proteins with chemotherapeutic agents to improve
drug response.
To summarize, we developed, validated at the histological and
genomic levels, and used five orthotopic patient-derived MPNST
xenografts, which were found to be an excellent resource for preclin-
ical investigation into this devastating tumor type. Our work points
to differences in the engraftment processes of primary tumors
compared with the engraftment of established cell lines. Results
presented here evidenced biological differences between the two
independent sporadic MPNSTs and the two NF1 MPNSTs developed
in the same patient, in terms of genomic composition, mutation
frequency and mutational signatures, immunohistochemical charac-
terization, and gene expression, although the number of tumors and
models analyzed here is still too low to drive any conclusion. Studies
providing a comprehensive characterization of a larger number of
sporadic and NF1-related MPNSTs are necessary to uncover possible
differences between these two groups of MPNSTs that could eventu-
ally be translated into different therapeutic strategies. The most
effective treatment tested in these preclinical models was sorafenib
in combination with doxorubicin or rapamycin, which highlights the
importance of combined drug therapy in achieving better therapeutic
outcomes. Genomic characterization will enable us to use these
orthoxenograft MPNST models in pharmacogenomic analysis.
Materials and Methods
Primary tumors and cell lines
Four fresh primary MPNSTs from three different patients were identi-
fied and removed at the Sarcoma Clinical Unit (UFTOS) of Bellvitge
Hospital (HUB) and the Catalan Institute of Oncology (ICO), both
institutions located on the IDIBELL campus. Two independent
MPNSTs were from one NF1 patient, and the other two were from
two different sporadic patients. After surgery, the tumor was sent to
our pathology service where it was analyzed following standard
protocols. Simultaneously, a piece of each tumor was stored in
DMEM, 10% FBS culture medium at room temperature before being
sent to our molecular unit. Once in our laboratory the tumor was
divided into sections, processed, and preserved in order to have mate-
rial for different purposes. Small pieces of each tumor were directly
frozen in liquid nitrogen so that DNA, RNA, and/or protein could be
obtained when needed. Small pieces were frozen in appropriate
culture media so that cell culture experiments or mice engraftments
could be performed. Informed consent was obtained from all subjects,
and the study received the approval of the IDIBELL Ethics Committee.
Animals
Six-week-old male nude Harlan mice weighing 18–22 g were used
in this study. Animals were housed in a sterile environment, in cages
with autoclaved bedding, food, and water. The mice were maintained
on a daily 12-h light, 12-h dark cycle. All experiments with mice
were approved by the IDIBELL Animal Care and Use Committee.
Human MPNST implantation and perpetuation
Fresh surgical specimens from 4 human MPNSTs were implanted in
athymic mice (Fig 1). The donor tumors were minced into small
fragments of 2–3 mm3 in size, and only macroscopically viable
tumor tissue was implanted in the upper thigh (orthotopic implanta-
tion, OT). Under isoflurane anesthesia, a subcutaneous pocket was
made with surgical scissors. Then, a small incision was made in the
muscle to display the sciatic nerve. A piece of tumor was grafted
there and grown surrounding the epineurium. The key points are
that the tumor is fixed to the surface of sciatic nerve with synthetic
monofilament, non-absorbable polypropylene suture (Prolene 7.0),
and that the epineurium was not breached. Primary tumors were
grafted orthotopically and subcutaneously in a minimum of three
different mice in the first passage. After implantation, tumor forma-
tion was checked weekly by palpation. Depending upon the intrinsic
characteristics of the primary tumor or cell line, orthotopic tumors
became apparent 1–3 months after engraftment. Once orthotopic
tumors had reached a volume of 1,000–1,500 mm3, mice were sacri-
ficed and tumors were passed to another animal. Between seven and
ten orthotopic mouse-to-mouse passages were performed for each
orthoxenograft. For each passage, at least three mice were implanted
in order to obtain a sufficient quantity of tumor material. After each
passage tumors were frozen, paraffin-embedded, and cryopreserved
to provide a source of viable tissue for future experiments.
The MPNST orthoxenograft procedure was approved by the
campus Animal Ethics Committee and complied with AAALAC
(Association for Assessment and Accreditation of Laboratory Animal
Care International) procedures.
The S462 cell line was kindly provided by Dr. Nancy Ratner.
S462 belongs to a NF1 patient carrying the c.6792C>A non-sense
mutation in exon 37. This patient developed a grade IV MPNST on
the thigh at age 19. The MPNSTs carried LOH in the NF1, TP53, and
CDK2NA genes. Cell line establishment was previously described
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(Frahm et al, 2004). To establish the orthoxenograft model from the
S462 NF1-MPNST cell line, we injected 0.3 ml of the cell suspension
(3 × 106 cells) with a needle directly in the upper thigh muscle
using Matrigel (a solubilized tissue basement membrane matrix rich
in extracellular matrix proteins). This enabled tumor growth around
the epineurium.
A total of 17 samples were obtained and analyzed in different
experiments: four primary MPNSTs, one cell line, six orthoxeno-
grafts in passage 1 and 6 orthoxenografts in passage 4 (for one of
the models, MPNST-NF1-001, two independent engraftments at
passages 1 and 4 were analyzed). Details of all tumors and the cell
line are provided in Table 1.
Presence of metastases
To investigate the capability of the orthoxenograft tumors to dissem-
inate in mice, the lungs, livers, and brains of 45 animals were histo-
logically examined by H&E staining. The five models were
examined after sacrifice for the presence of synchronic micrometas-
tases.
A subgroup of 15 orthotopically implanted mice (the two sporadic
models and MPNST-NF1-001) was kept alive for 4–6 months
after tumor removal to investigate the dissemination capabilities
over a longer time frame (metachronic micrometastases).
Nucleic acid preparation
DNA
GentraPuragene Kit (Qiagen) was used for DNA isolation of frozen
human and xenograft tumors, according to manufacturer’s recom-
mendations, after homogenization using TissueLyser (Qiagen). DNA
quality and quantity were assessed by visual inspection in an
agarose gel and with NanoDrop and PicoGreen.
RNA
Total RNA was isolated from frozen samples using miRCURY RNA
(Exiqon). RNA integrity number (RIN) was verified for each sample
using a RNA Nano Chip Kit (Agilent Technologies, Germany) in
Agilent Bioanalyzer 2100.
Immunohistochemistry analysis
Paraffin-embedded human primary and mouse orthoxenograft
MPNST sections (3–5 lm) were deparaffinized in xylene and gradu-
ally rehydrated. Endogenous peroxidases were blocked by incuba-
tion with hydrogen peroxide (H2O2 3%, for 20 min), and antigen
retrieval was performed by heating tissue sections for 20 min in
citrate buffer (pH = 6 or pH = 9 depending on the antibody manu-
facture’s protocol). Blocking was performed by incubation for
20 min with 10% horse serum. The primary antibodies vimentin
(1:500, IR630, DAKO), Desmin (IR606, DAKO), actin (1:50, M0851,
DAKO), EMA (1:200, IR629, DAKO), CD34 (IR632, DAKO), S100
(IS504, DAKO), P53 (IR616, DAKO), and Ki-67 (1:75; M7240,
DAKO) were incubated overnight at 4°C following the manufac-
turer’s guidelines. Secondary HPRT-conjugated antibody (Envision,
DAKO, Denmark) was incubated at room temperature for 30 min.
Finally, development was performed by incubation with diam-
inobenzidine (DAB) (DAKO, Denmark) for 10 min. Nuclei were
counterstained with hematoxylin. For stroma analysis, primary anti-
bodies rat anti-mouse CD34 (1:100, 8158, Abcam) and mouse anti-
human CD34 (1:100, 8536, Abcam) were incubated overnight at
4°C. Secondary HPRT anti-mouse-conjugated antibody (Envision,
DAKO, Denmark) or biotinylated anti-rat (Daki, Denmark; 1:200
dilution) were incubated at room temperature for 60 min.
Sanger sequencing
c.350T>A mutation region of blood, primary tumors, and orthotopic
xenograft tumor was sequenced by PCR amplification using specific
primers targeting the mutation region of the NF1 gene and the
BigDye Terminator v.3.1 Sequencing Kit (Applied Biosystems, Carls-
bad, CA). Sequences were analyzed on an ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, CA, USA).
SNP array analysis
SNP array analysis was performed on all 17 samples using Beadchip
technology from Illumina, but with different chips depending on
availability at the time of the analysis (Supplementary Table S3). In
particular, two samples were analyzed using Illumina Human660W-
Quad chip (655,246 SNPs), six samples using Illumina HumanOmni-
Express v1 (730,525 SNPs), and nine samples using Illumina
HumanOmni1S (1,185,076 SNPs). In all cases, raw data were
processed with Illumina Genome Studio v2009 with the Genotyping
module v1.1.9 to extract B-allele frequency (BAF) and log R ratio
(LRR) values for each SNP.
SNP array data were analyzed using the R package ASCAT (Van
Loo et al, 2010) to obtain loss-of-heterozygosity (LOH) and allele-
specific copy number (CN) profiles from the BAF and LRR values.
All samples were analyzed independently and treated as unpaired
samples, using the germline genotype prediction functionality from
ASCAT. In short, after loading BAF and LRR data, the germline
genotype parameters were estimated and the data were segmented
using the ASPCF algorithm. Next, ASCAT computed the most likely
combination of CN states, total ploidy and percentage of aberrant
cells. Circular genomic plots were created using Circos (Krzywinski
et al, 2009).
Exome sequencing
Exome sequence capture and amplification was performed in all
primary tumors and constitutional DNA from the different patients,
in the S462 cell line, and in all orthoxenograft models at passage 1
and NF1-MPNST-001 passage 4, using Agilent SureSelect Human All
Exon kit (Agilent, Santa Clara, CA, US) according to the manufac-
turer’s instructions. Paired-end sequencing was performed on a
HiSeq2000 instrument (Illumina) using 76-base reads. Reads were
aligned to the reference genome (GRCh37), and a BAM file was
generated using SAMtools. PCR duplicates were removed using
SAMtools and custom scripts, and single-nucleotide variant calling
was performed using a combination of SAMtools and Sidro´n as
described previously (Puente et al, 2011). For orthoxenograft-
derived samples, reads were first aligned to mouse genome (mm9),
and those read-pairs which did not align to mouse were then aligned
to the human genome following the same pipeline as above. This
procedure removed murine-derived reads, which might interfere in
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the analysis by artificially increasing the number of variants.
However, this could lead to the removal of certain human genes
with a very high DNA sequence identity to mouse DNA and caused
some true changes to be overlooked. Variants detected in the tumor
sample that were not present in the matching constitutional DNA
were considered somatic variants (Supplementary Table S1). For
the validation analysis, only mismatch variants were taken into
account. Common variants, defined as those present in dbSNP135
with a minor allele frequency > 1%, were filtered out. For all vari-
ants identified in primary tumors and in the orthoxenografts, bam-
readcount was used to check whether they were supported by a read
in the other related samples; variants were considered to be present
if there was at least one read with a quality of over 20. These data
were used to identify somatic mutations as well as gained mutations
(variants present in the xenograft but not found in the primary
tumor) and lost mutations (variants identified in the primary tumor
but not detected in the xenograft). Analysis of the genomic context
of the C>T variants was performed using R and Bioconductor.
Expression microarray analysis
Gene expression profiles were determined using Affymetrix Human
Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA) following standard
protocols. Expression data were analyzed using R version 3.0.2
(Dean & Nielsen, 2007) and the Bioconductor (Gentleman et al,
2004) package Affy (Gautier et al, 2004). Raw CEL files were
normalized with RMA, and the normalized expression values were
extracted. Samples were compared at the level of normalized expres-
sion values using the Pearson correlation coefficient to quantify the
changes between primary tumors and the derived orthoxeno-
grafts. Expression profiles were classified using a hierarchical
clustering approach with Euclidean distance and average as agglom-
eration method. Heatmaps represent the Pearson correlation
between pairs of samples and were drawn using the gplots library.
Drug treatment
To prepare each drug treatment, an early-passage (P2–P4) orthoxe-
nograft tumor had to be expanded. To do this, each tumor was
implanted in five mice. When tumors reached a minimum size of
1,000–1,500 mm3, mice were sacrificed, tumors were harvested and
cut into small fragments, and the tumor fragments were grafted into
50–70 mice, depending on the size of the experiment. When the
tumors reached a homogeneous size of 1,000–1,500 mm3, they were
randomly distributed into different treatment groups (n = 7–10/
group). Seven treatment regimens were tested: (i) doxorubicin; (ii)
intraperitoneal rapamycin; (iii) oral rapamycin; (iv) sorafenib; (v)
doxorubicin plus oral rapamycin; (vi) doxorubicin plus sorafenib;
and (vii) oral rapamycin plus sorafenib. Drugs were administered as
follows: mice were given an intraperitoneal injection of doxorubicin
(8 mg/kg) once, at the beginning of the treatment; a daily oral or
intraperitoneal dose of rapamycin (5 mg/kg); and a daily oral
gavage dose of sorafenib (60 mg/kg). Rapamycin was obtained from
Novartis Pharmaceuticals Corporation (East Hanover, NJ). Rapa-
mycin was administered in a microemulsion solvent composed of
50% olive oil for the oral dosage and diluted in 10% DMSO; for the
intraperitoneal dosage, it was diluted in 0.5% w/v carboxyl methyl-
cellulose (Sigma; Johansson et al, 2008). Sorafenib was purchased
from LC Laboratories (Woburn, MA) and dissolved in 50% cremo-
phor EL (Sigma, St. Louis, MO)—50% ethanol. The mixture was
vortexed for 30–60 min to dissolve sorafenib and then dissolved in
75% water immediately prior to oral gavage (Wu et al, 2012). Doxo-
rubicin dose was chosen on the basis of studies in which intraperito-
neal administration at 8 mg/kg was tested in a xenograft model
derived from a MPNST cell line (Johansson et al, 2008). Rapamycin
administered intraperitoneally at 5 mg/kg was used previously in a
genetically engineered MPNST mouse model (Johannessen et al,
2008), and the sorafenib dose was chosen on the basis of preclinical
studies in which daily oral administration of Sorafenib at 30–60
mg/kg was tested in several tumor models (Wilhelm et al, 2004). A
mouse control group receiving no drug was used for each drug treat-
ment experiment. In the first drug experiment, using mice MPNST-
NF1-001, two additional control groups were treated with the two
vehicles for oral rapamycin and sorafenib administration. No signifi-
cant differences in tumor response were observed between the
different vehicles relative to the untreated group. Thus, to simplify
the presentation of data, we have included only one control group
per model, which corresponds to the untreated animals.
In the drug response and metastasis experiments, the majority of
mice were sacrificed when tumors reached sizes between 2,000 and
2,500 mm3. After sacrifice, tumors were dissected out, measured,
and weighed. Representative fragments were frozen in liquid nitro-
gen and fixed and paraffin-embedded.
Overall treatment time varied slightly between experiments,
between 12 and 25 days, according to the intrinsic differences in
tumor growth. The duration of the drug response treatment was
always marked by the tumor size of the matching control group,
which complied with our institution’s and international standard
The paper explained
Problem
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive
soft-tissue sarcomas with poor survival for which no effective therapy
is available. In 50% of cases, they occur in the context of neurofibro-
matosis type I; the remainder arises sporadically. Current in vivo
tumor models of MPNSTs are limited to models derived from estab-
lished cancer cell lines. In vivo models are needed that better recapit-
ulate human MPNSTs and that could be used to assess effective,
standardized therapies.
Results
We generated five distinct MPNST orthoxenograft models (four are
patient-derived tumor xenografts (PDTX) and one is an orthoxenograft
derived from an NF1-related MPNSTs cell line) that were exhaustively
characterized by histopathological analysis, SNP array, exome
sequencing, and expression array analysis. We demonstrated that all
orthoxenograft models recapitulate each of the features of their
parental primary tumors and proved that they are excellent preclinical
models for drug treatment trials. Finally, therapeutic experimentation
with sorafenib—either alone or, more effectively, in combination with
doxorubicin or rapamycin—greatly reduced tumor growth in all
models, supporting their use to treat patients with MPNSTs.
Impact
Our work reports the creation of the first patient-derived MPNST
orthoxenograft model resource available for preclinical testing. The
results strongly support the clinical use of sorafenib in these patients.
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animal ethics protocols. Briefly, MPNST-NF1-001 treatments lasted
12 days, MPNST-NF1-002 treatments lasted 22 days, MPNST-SP-001
treatments lasted 14 days, MPNST-SP-002 treatments lasted 25 days,
and MPNST-NF1-S462 treatments lasted 19 days. After treatment
initiation, tumors were measured using a caliper every 2–3 days and
tumor volume was calculated using the formula v = (w2 l/2), where
l is the longest diameter and w the width. Changes in tumor volume
were quantified as the log2 ratio between observed and baseline
volume. The rate of change in volume across different treatment
categories was modeled using linear mixed models (LMM). The
interaction between follow-up time (in days) and treatment was used
to assess the effect of each treatment in terms of volume change and
compared to the control group. Significance was tested by the Wald
test, and P-values were adjusted by Bonferroni’s correction to
address the problem of multiple comparisons due to multiple testing
(Supplementary Table S4). All tests were two-sided, and significance
level was set at 0.05. Analyses were also repeated after exclusion of
mice that died during follow-up, with no appreciable impact on
results (data not shown). The analyses were performed using Stata
v10 (StataCorp LP, College Station, Texas).
For long-term studies, a subgroup of treated mice (n = 3–5 mice/
group) was kept alive for a maximum period of 4 months and sacri-
ficed over time when relapsed tumor masses grew as large solid
masses (usually 1,500–2,000 mm3). For the characterization of
histopathological response in post-chemotherapy MPNSTs, we
examined all cases to evaluate the following histological features:
mitotic rate expressed as the number of mitotic figures per 10 high-
power fields (1 field, 0.164 mm2) and necrosis. For each tumor,
mitotic rate and necrosis were estimated on whole transverse
sections from three areas (Dutour et al, 2009).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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